Ana Chopitea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ana Chopitea has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
J. Rodriguez
Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain
15 shared publicationsJ. Garcia-Foncillas
12 shared publicationsJavier Rodriguez
Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
11 shared publicationsA. Viudez
Clinica Universitaria de Navarra, Pamplona, Spain; University of Navarra, Pamplona, Spain; Clinica Universidad de Navarra, Pamplona, Spain
10 shared publications- Javier Aristu
Department of Radiation Oncology, Clinica Universidad de Navarra, 28027 Madrid, Spain
9 shared publications L. Arbea
Department of Oncology, Unit for the Research and Treatment of Gastrointestinal Cancer, Clínica Universidad de Navarra, University of Navarra, Avenida Pío XII 36, 31008, Pamplona, Spain
8 shared publications
Latest Publications
- 28 July 2020
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 30 (4) , 293-295
Successful Desensitization to Oxaliplatin After a Single Initial Dose of Omalizumab in a Patient With Elevated IgE Levels
- 28 July 2020
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 30 (4) , 293-295
Successful Desensitization to Oxaliplatin After a Single Initial Dose of Omalizumab in a Patient With Elevated IgE Levels
- Open Access
- 9 May 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0215970
Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling
Perioperative chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC) has been shown to improve survival compared to an exclusive surgical approach. However, most patients retain a poor prognosis due to important relapse rates. Population pharmacokinetic-pharmacodynamic (PK/PD) modeling may allow identifying at risk-patients. We aimed to develop a mechanistic PK/PD model to characterize the relationship between the type of neoadjuvant therapy, histopathologic response and survival times in locally advanced GC and GEJC patients. Patients with locally advanced GC and GEJC treated with neoadjuvant CT with or without preoperative CRT were analyzed. Clinical response was assessed by CT-scan and EUS. Pathologic response was defined as a reduction on pTNM stage compared to baseline cTNM. Metastasis development risk and overall survival (OS) were described using the population approach with NONMEM 7.3. Model evaluation was performed through predictive checks. A low correlation was observed between clinical and pathologic TNM stage for both T (R = 0.32) and N (R = 0.19) categories. A low correlation between clinical and pathologic response was noticed (R = -0.29). The OS model adequately described the observed survival rates. Disease recurrence, cTNM stage ≥3 and linitis plastica absence, were correlated to a higher risk of death. Our model adequately described clinical response profiles, though pathologic response could not be predicted. Although the risk of disease recurrence and survival were linked, the identification of alternative approaches aimed to tailor therapeutic strategies to the individual patient risk warrants further research.
- 9 May 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0215970
Open AccessNeoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling
Perioperative chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC) has been shown to improve survival compared to an exclusive surgical approach. However, most patients retain a poor prognosis due to important relapse rates. Population pharmacokinetic-pharmacodynamic (PK/PD) modeling may allow identifying at risk-patients. We aimed to develop a mechanistic PK/PD model to characterize the relationship between the type of neoadjuvant therapy, histopathologic response and survival times in locally advanced GC and GEJC patients. Patients with locally advanced GC and GEJC treated with neoadjuvant CT with or without preoperative CRT were analyzed. Clinical response was assessed by CT-scan and EUS. Pathologic response was defined as a reduction on pTNM stage compared to baseline cTNM. Metastasis development risk and overall survival (OS) were described using the population approach with NONMEM 7.3. Model evaluation was performed through predictive checks. A low correlation was observed between clinical and pathologic TNM stage for both T (R = 0.32) and N (R = 0.19) categories. A low correlation between clinical and pathologic response was noticed (R = -0.29). The OS model adequately described the observed survival rates. Disease recurrence, cTNM stage ≥3 and linitis plastica absence, were correlated to a higher risk of death. Our model adequately described clinical response profiles, though pathologic response could not be predicted. Although the risk of disease recurrence and survival were linked, the identification of alternative approaches aimed to tailor therapeutic strategies to the individual patient risk warrants further research.
- Open Access
- 29 September 2018
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 96
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a clear tendency to fewer and later relapses in the vaccine arm (median disease free survival –DFS-) 25.26 months, 95% CI 8.74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32–18.88).
- 29 September 2018
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 96
Open AccessA randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a clear tendency to fewer and later relapses in the vaccine arm (median disease free survival –DFS-) 25.26 months, 95% CI 8.74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32–18.88).
- 1 September 2018
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 29 (9) , 1305-1306
Segmental Pneumonitis after Radioembolization
- 1 September 2018
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 29 (9) , 1305-1306
Segmental Pneumonitis after Radioembolization
- 14 August 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (16) , 3787-3789
Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center
Although molecular subtype–based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from formalin-fixed paraffin-embedded (FFPE) specimens should be considered to create combined models that better define individual patients' needs. Clin Cancer Res; 24(16); 3787–9. ©2018 AACR. See related article by Kandimalla et al., p. 3867
- 14 August 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (16) , 3787-3789
Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center
Although molecular subtype–based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from formalin-fixed paraffin-embedded (FFPE) specimens should be considered to create combined models that better define individual patients' needs. Clin Cancer Res; 24(16); 3787–9. ©2018 AACR. See related article by Kandimalla et al., p. 3867
- 17 October 2017
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 20 (5) , 658-665
Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience
Synchronous liver metastases (LM) from gastric (GC) or esophagogastric junction (EGJ) adenocarcinoma are a rare events. Several trials have evaluated the role of liver surgery in this setting, but the impact of preoperative therapy remains undetermined.
- 17 October 2017
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 20 (5) , 658-665
Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience
Synchronous liver metastases (LM) from gastric (GC) or esophagogastric junction (EGJ) adenocarcinoma are a rare events. Several trials have evaluated the role of liver surgery in this setting, but the impact of preoperative therapy remains undetermined.
- Open Access
- 18 August 2016
- Published by Springer Nature in British Journal of Cancer
- Vol. 115 (6) , 655-663
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.
- 18 August 2016
- Published by Springer Nature in British Journal of Cancer
- Vol. 115 (6) , 655-663
Open AccessRole of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.
- 5 August 2016
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 19 (3) , 379-385
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery
Neoadjuvant chemotherapy is being actively tested as an emerging alternative for the treatment of locally advanced colon cancer (LACC) patients, resembling its use in other gastrointestinal tumors. This study assesses the mid-term oncologic outcome of LACC patients treated with oxaliplatin and fluoropyrimidines-based preoperative chemotherapy followed by surgery. Patients with radiologically resectable LACC treated with neoadjuvant therapy between 2009 and 2014 were retrospectively analyzed. Radiological, metabolic, and pathological tumor response was assessed. Both postoperative complications, relapse-free survival (RFS), and overall survival (OS) were studied. Sixty-five LACC patients who received treatment were included. Planned treatment was completed by 93.8 % of patients. All patients underwent surgery without delay. The median time between the start of chemotherapy and surgery was 71 days (65–82). No progressive disease was observed during preoperative treatment. A statistically significant tumor volume reduction of 62.5 % was achieved by CT scan (39.8–79.8) (p < 0.001). It was also observed a median reduction of 40.5 % (24.2–63.7 %) (p < 0.005) of SUVmax (Standard Uptake Value) by PET-CT scan. Complete pathologic response was achieved in 4.6 % of patients. Postoperative complications were observed in 15.4 % of patients, with no cases of mortality. After a median follow-up of 40.1 months, (p25–p75: 27.3–57.8) 3–5 year actuarial RFS was 88.9–85.6 %, respectively. Five-year actuarial OS was 95.3 %. Preoperative chemotherapy in LACC patients is safe and able to induce major tumor regression. Survival times are encouraging, and further research seems warranted.
- 5 August 2016
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 19 (3) , 379-385
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery
Neoadjuvant chemotherapy is being actively tested as an emerging alternative for the treatment of locally advanced colon cancer (LACC) patients, resembling its use in other gastrointestinal tumors. This study assesses the mid-term oncologic outcome of LACC patients treated with oxaliplatin and fluoropyrimidines-based preoperative chemotherapy followed by surgery. Patients with radiologically resectable LACC treated with neoadjuvant therapy between 2009 and 2014 were retrospectively analyzed. Radiological, metabolic, and pathological tumor response was assessed. Both postoperative complications, relapse-free survival (RFS), and overall survival (OS) were studied. Sixty-five LACC patients who received treatment were included. Planned treatment was completed by 93.8 % of patients. All patients underwent surgery without delay. The median time between the start of chemotherapy and surgery was 71 days (65–82). No progressive disease was observed during preoperative treatment. A statistically significant tumor volume reduction of 62.5 % was achieved by CT scan (39.8–79.8) (p < 0.001). It was also observed a median reduction of 40.5 % (24.2–63.7 %) (p < 0.005) of SUVmax (Standard Uptake Value) by PET-CT scan. Complete pathologic response was achieved in 4.6 % of patients. Postoperative complications were observed in 15.4 % of patients, with no cases of mortality. After a median follow-up of 40.1 months, (p25–p75: 27.3–57.8) 3–5 year actuarial RFS was 88.9–85.6 %, respectively. Five-year actuarial OS was 95.3 %. Preoperative chemotherapy in LACC patients is safe and able to induce major tumor regression. Survival times are encouraging, and further research seems warranted.
- 1 June 2015
- Vol. 107 (6) , 340-6
Long-term oncologic results in cancer of the rectum treated by preoperative chemoradiotherapy and surgery: An analysis of 500 cases.
The standard treatment for locally advanced cancer of the rectum (LACR) and selective cases of stage IV disease is preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME). Despite reductions in local recurrence, disease-free survival (DSF) has remained stable in recent years. The objective of this study is to analyze patterns of recurrence, long-term survival and prognostic factors in a program of neoadjuvant CRT and surgery in LACR. Between January 1992 and December 2011, 446 patients with LACR and 54 patients (with single metastases) were treated with pre-operative long course CRT and surgery. Three hundred forty four (66.8%) anterior resections of the rectum and 123 (24.6%) abdomino-perineal resections were performed. With a mean follow-up of 70.06 months, local recurrence was 4.8% and distant recurrence 25.5%. No differences were found in the histopathologic prognostic factors across the three groups studied depending on distance (cm) from the analmargin. Involvement of the circumferential resection margin (CRM+) was significantly greater in tumors in the distal third of the rectum (8.5%; p = 0.04). 67 patients (13.4%) showed a complete pathologic response. DSF at 5 and 10 years was significantly lower in patients with tumors affecting the distal third as compared to the middle third of the rectum (61.9% vs. 57.7%; p = 0.04). Tumors at this distal location resulted in a significantly higher incidence of lung metastases (p = 0.016).
- 1 June 2015
- Vol. 107 (6) , 340-6
Long-term oncologic results in cancer of the rectum treated by preoperative chemoradiotherapy and surgery: An analysis of 500 cases.
The standard treatment for locally advanced cancer of the rectum (LACR) and selective cases of stage IV disease is preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME). Despite reductions in local recurrence, disease-free survival (DSF) has remained stable in recent years. The objective of this study is to analyze patterns of recurrence, long-term survival and prognostic factors in a program of neoadjuvant CRT and surgery in LACR. Between January 1992 and December 2011, 446 patients with LACR and 54 patients (with single metastases) were treated with pre-operative long course CRT and surgery. Three hundred forty four (66.8%) anterior resections of the rectum and 123 (24.6%) abdomino-perineal resections were performed. With a mean follow-up of 70.06 months, local recurrence was 4.8% and distant recurrence 25.5%. No differences were found in the histopathologic prognostic factors across the three groups studied depending on distance (cm) from the analmargin. Involvement of the circumferential resection margin (CRM+) was significantly greater in tumors in the distal third of the rectum (8.5%; p = 0.04). 67 patients (13.4%) showed a complete pathologic response. DSF at 5 and 10 years was significantly lower in patients with tumors affecting the distal third as compared to the middle third of the rectum (61.9% vs. 57.7%; p = 0.04). Tumors at this distal location resulted in a significantly higher incidence of lung metastases (p = 0.016).
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e15220
A pilot study of oxaliplatin, irinotecan and PK-adjusted 5-fluorouracil within a neoadjuvant multidisciplinary approach in locally advanced pancreatic cancer patients.
E15220 Background: The aim of this study was to evaluate the feasibility and efficacy of FOLFOXIRI induction chemotherapy (ICT) with pharmacokinetic (PK) dose adjustment of 5-FU followed by chemo-radiotherapy (CRT) and surgery (S) in Locally Advanced Pancreatic Cancer patients (pts) Methods: Borderline resectable and unresectableLAPC pts with EUS stages T3-4/N+ were included. ICT consisted of 4 cycles of Oxalipatin (85mg/m²), Leucovorin (400mg/m²), Irinotecan (150mg/m²) and 5-FU [initial dose of 3200mg/m² in 46h; subsequent doses based on PK-guided dose adjustments (therapeutic AUC of 20-30 mg∙h∙L-1)]. 5-FU concentrations were analyzed by High-performanced Liquid Chromatography. PK parameters were estimated by Bayesian Methodology with Multiple Dose Software. Pts with no progressive disease after ICT were planned to receive CRT. Surgery (S) was planned 4 to 6 weeks after completion of CRT. Toxicity was recorded according to the NCI-CTCAE 4.0 Results:From November 2011 to August 2014, 23 LAPC treatment-naï...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e15220
A pilot study of oxaliplatin, irinotecan and PK-adjusted 5-fluorouracil within a neoadjuvant multidisciplinary approach in locally advanced pancreatic cancer patients.
E15220 Background: The aim of this study was to evaluate the feasibility and efficacy of FOLFOXIRI induction chemotherapy (ICT) with pharmacokinetic (PK) dose adjustment of 5-FU followed by chemo-radiotherapy (CRT) and surgery (S) in Locally Advanced Pancreatic Cancer patients (pts) Methods: Borderline resectable and unresectableLAPC pts with EUS stages T3-4/N+ were included. ICT consisted of 4 cycles of Oxalipatin (85mg/m²), Leucovorin (400mg/m²), Irinotecan (150mg/m²) and 5-FU [initial dose of 3200mg/m² in 46h; subsequent doses based on PK-guided dose adjustments (therapeutic AUC of 20-30 mg∙h∙L-1)]. 5-FU concentrations were analyzed by High-performanced Liquid Chromatography. PK parameters were estimated by Bayesian Methodology with Multiple Dose Software. Pts with no progressive disease after ICT were planned to receive CRT. Surgery (S) was planned 4 to 6 weeks after completion of CRT. Toxicity was recorded according to the NCI-CTCAE 4.0 Results:From November 2011 to August 2014, 23 LAPC treatment-naï...